AQP4 and myeloid sarcoma: Heterogeneity in age at onset, disease course (monophasic versus relapsing), therapies utilized, clinical course, pathology and antibody titers in MOGAD patients in this study is consistent with the literature on MOGAD [34], but clear differences remain from MS and AQP4-IgG-seropositive NMOSD that suggest MOGAD is a distinct entity.